These included a competitive binding experiment, where mice bearing LNCaP tumors received either 111In-PSMA-NARI-56 alone (Figure 2A) or co-administered with a 100-fold molar excess of unlabeled PSMA-NARI-56 (Figure 2B), and a second assay using PC-3 tumor-bearing mice, which lack PSMA expression (Figure 2C). The gene discussed is FOLH1; the disease is neoplasm.